Fierce Healthcare December 7, 2022
Teresa Carey

The healthcare industry is grappling with rising drug prices. The expectation is, though, that the wave of biosimilars launching next year will make a dent in healthcare costs. Paige Minemyer interviews Alan Lotvin, M.D., president of CVS Health’s Caremark pharmacy benefit manager, about biosimilars’ potential.


Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
J&J to shut down massive Bay Area R&D facility less than 18 months after opening it
Molecular “Super Glue”? How Our Body Repairs Broken DNA
Lose Fat, Not Muscle: Next Test for Lilly’s Zepbound Pairs It With BioAge Drug
FDA Updates for the Week of Feb 19: Cancer Approval Revoked
FDA Approves Simlandi, Third Interchangeable Humira Biosimilar

Share This Article